-

02:21:56 AM

OGEN Stock News

OGEN - Oragenics Inc

12/23/22 4:05 PM

AMEX : OGEN

low float

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that its Board of Directors on December 22, 2022 approved a 1- for-60 reverse stock split of the Company’ s issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the Company’ s...

RHEA-AI

neutral

12/22/22 7:30 AM

AMEX : OGEN

covid-19low float

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

Oragenics, Inc., a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate.

RHEA-AI

neutral

12/20/22 4:36 PM

AMEX : OGEN

low float

Oragenics, Inc. Receives NYSE American Notice

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that it received a Notice on December 19, 2022 from the NYSE American LLC stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003 of the NYSE American Company Guide. The Company’ s receipt of...

RHEA-AI

neutral

12/19/22 4:34 PM

AMEX : OGEN

low float

Oragenics, Inc. Announces New Chair

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that on December 16, 2022 the Board of Directors appointed Charles Pope as its Chairman of the Board of Directors succeeding Dr. Dr. Telling stated:“ It has been an honor and privilege to serve as Chairman of Oragenics for over a decade and I look...

RHEA-AI

very positive

10/24/22 4:01 PM

AMEX : OGEN

conferenceslow float

Oragenics to Participate in the 2022 BioFlorida Annual Conference

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami. Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and...

RHEA-AI

neutral

09/30/22 7:30 AM

AMEX : OGEN

low float

Oragenics Issues Letter to Shareholders

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued the following letter to shareholders from its President and Chief Executive Officer, Kim Murphy. As most of you know, in late June I took over the day-to-day leadership of Oragenics from Fred Telling, and we are fortunate that Fred remains a...

RHEA-AI

neutral

08/24/22 7:00 AM

AMEX : OGEN

covid-19low float

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, today announced favorable preliminary results from its ongoing Good Laboratory Practice toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine candidate in rabbits. Oragenics previously published positive...

RHEA-AI

neutral

06/23/22 4:30 PM

AMEX, Nasdaq : OGEN, BWV, CRXT

managementlow float

Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck’ s HPV/Gardasil Franchise.

RHEA-AI

very positive

06/14/22 7:30 AM

AMEX : OGEN

covid-19low float

Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored by Oragenics and collaborators at Inspirevax and the National Research Council of Canada Human Health Therapeutics Research Centre in Scientific Reports, a Nature journal. These published data, and our...

RHEA-AI

neutral

05/17/22 7:30 AM

AMEX : OGEN

low float

Oragenics Issues Letter to Shareholders

Oragenics, Inc. today issued the following letter to shareholders from its Executive Chairman, Frederick W. Telling, Ph.D.:. I thank you for your continued support of Oragenics and our vision, and am delighted to report on our recent progress. In previous letters I affirmed the strategic direction Oragenics is taking and discussed our commitment to the speedy yet...

RHEA-AI

neutral

OGEN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.oragenics.com
Security nameOragenics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees7
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address4902 Eisenhower Blvd Ste 125
StateFlorida
CityTampa
Zip33634-6342
CountryUS
Phone18132867900

About Oragenics Inc

Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. The Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from novel coronavirus. The Terra CoV-2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health. In addition, Oragenics has an exclusive worldwide channel collaboration with ILH Holdings, Inc. (n/k/a Eleszto Genetika, Inc.), relating to the development of novel lantibiotics.